IL-29/IFN-lambda 1 Antibody (247801) [Unconjugated]

Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-29/IFN-lambda 1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anri-Human IL-29/IFN-lambda 1 Monoclonal Antibody (Catalog # MAB15981). The ND50 is typically 1-4 µg/mL.

• Reactivity: Hu
• Applications: B/N, ELISA(Cap)
• Clone: 247801
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-29/IFN-lambda 1 Antibody (247801) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL-29/IFN-lambda 1
  Gly20-Thr200
  Accession # Q8IU54
• Specificity: Detects human IL-29/IFN-lambda 1 in ELISAs. In sandwich immunoassays, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL‑28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN‑ beta 1A.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: IFNL1
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 1-4 ug/mL
• Application Notes: ELISA Capture: Human IL-29/IFN-lambda 1 Antibody (Catalog # MAB15981)
  ELISA Detection: Human IL-29/IFN-lambda 1 Biotinylated Antibody (Catalog # BAF1598)
  Standard: Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-29/IFN-lambda 1 Antibody (247801) [Unconjugated]

• cytokine Zcyto21
• IFNL1
• IFN-lambda 1
• IFN-lambda-1
• IL29
• IL-29
• interferon lambda-1
• interferon, lambda 1
• interleukin 29 (interferon, lambda 1)
• interleukin-29
• ZCYTO21

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and the type I IFN family (15‑19% aa sequence identity) (1‑3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-29/IFN-lambda 1 Antibody (MAB15981)(15)

Publications using MAB15981

• Groen, K;Kuratli, R;Sar, L;Vasou, A;Huber, M;Hughes, DJ;Hale, BG; Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies European journal of immunology 2024-10-04 [PMID: 39367550] (Neutralization, Human)
• J Hong, JH Lee, Z Zhang, Y Wu, M Yang, Y Liao, R de la Rosa, J Scheirer, D Pechacek, N Zhang, Z Xu, T Curiel, X Tan, TH Huang, K Xu PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer Cancer Research, 2022-12-16;0(0):. 12/16/2022 [PMID: 36222718]
• Ee Shan Pang, Ghazal Daraj, Katherine R. Balka, Dominic De Nardo, Christophe Macri, Hubertus Hochrein et al. Discordance in STING-Induced Activation and Cell Death Between Mouse and Human Dendritic Cell Populations Frontiers in Immunology 2/25/2022 [PMID: 35281062]
• Conor N. Gruber, Roosheel S. Patel, Rebecca Trachtman, Lauren Lepow, Fatima Amanat, Florian Krammer et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) Cell 11/1/2020 [PMID: 32991843]
• M Essaidi-La, J Geiser, S Huang, S Constant, L Kaiser, C Tapparel Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway Epithelia Sci Rep, 2020-06-24;10(1):10246. 2020-06-24 [PMID: 32581261] (Bioassay, Human)
• V Oke, I Gunnarsson, J Dorschner, S Eketjäll, A Zickert, TB Niewold, E Svenungsso High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus Arthritis Res. Ther., 2019-04-29;21(1):107. 2019-04-29 [PMID: 31036046] (ELISA Capture, Human)
• Sultan Doğanay, Maurice Youzong Lee, Alina Baum, Jessie Peh, Sun-Young Hwang, Joo-Yeon Yoo et al. Single-cell analysis of early antiviral gene expression reveals a determinant of stochastic IFNB1 expression Integrative Biology 11/13/2017 [PMID: 29098213]
• V Oke, S Brauner, A Larsson, J Gustafsson, A Zickert, I Gunnarsson, E Svenungsso IFN-?1 with Th17 axis cytokines and IFN-? define different subsets in systemic lupus erythematosus (SLE) Arthritis Res. Ther., 2017-06-15;19(1):139. 2017-06-15 [PMID: 28619037] (Human)
• Iva Gunnarsson Interferon (IFN)-? is a potential mediator in lupus nephritis Lupus Sci Med, 2016-11-22;3(1):e000170. 2016-11-22 [PMID: 27933198] (ELISA Development (Capture), Human)
• Villenave R, Broadbent L, Douglas I, Lyons J, Coyle P, Teng M, Tripp R, Heaney L, Shields M, Power U Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium. J Virol, 2015-09-30;89(24):12309-18. 2015-09-30 [PMID: 26423940] (Neutralization, Human)
• Persson B, Jaffe A, Fearns R, Danahay H Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE, 2014-07-17;9(7):e102368. 2014-07-17 [PMID: 25033192] (Neutralization, Human)
• Brownell J, Bruckner J, Wagoner J, Thomas E, Loo Y, Gale M, Liang T, Polyak S Direct, interferon-independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection. J Virol, 2013-11-20;88(3):1582-90. 2013-11-20 [PMID: 24257594] (Neutralization, Human)
• Brownell J, Wagoner J, Lovelace E, Thirstrup D, Mohar I, Smith W, Giugliano S, Li K, Crispe I, Rosen H, Polyak S Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J Hepatol, 2013-06-12;59(4):701-8. 2013-06-12 [PMID: 23770038] (Neutralization, Human)
• Stone , Amy E L, Giugliano , Silvia, Schnell , Gretja, Cheng , Linling, Leahy , Katelyn, Golden-Mason , Lucy, Gale , Michael, Rosen , Hugo R Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog, 2013-04-18;9(4):e1003316. 2013-04-18 [PMID: 23637605] (Neutralization, Human)
• Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute S, Garrigues U, Doyle S, Donnelly R, Kotenko S, Fitzgerald-Bocarsly P Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol, 2012-08-13;189(6):2735-45. 2012-08-13 [PMID: 22891284] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: IFNL1
• Uniprot:
  • Q8IU54()